Outcomes after extended azithromycin administration in preterm premature rupture of membranes.

antibiotics in pregnancy, chorioamnionitis preterm premature rupture of membranes

Journal

AJOG global reports
ISSN: 2666-5778
Titre abrégé: AJOG Glob Rep
Pays: United States
ID NLM: 101777907

Informations de publication

Date de publication:
May 2023
Historique:
medline: 22 5 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: epublish

Résumé

Preterm premature rupture of membranes accounts for approximately one-quarter of all preterm deliveries and occurs in 2% to 3% of all pregnancies. With subclinical infection being a suspected cause of preterm premature rupture of membranes, the administration of prophylactic antibiotics is an accepted standard of care to extend the latency period. Historically, erythromycin was used in the antibiotic regimen recommended for women with preterm premature rupture of membranes during expectant management; however, azithromycin has recently been shown to be a suitable alternative. This study aimed to evaluate whether extended azithromycin administration affects the latency time in preterm premature rupture of membranes. This was a retrospective multi-institutional cohort study in Washington, District of Columbia, of patients admitted from January 2012 to December 2019 with preterm premature rupture of membranes of singleton pregnancies between 23 0/7 and 33 6/7 weeks of gestation. Patients were excluded if they had multiple pregnancies, had an allergy to penicillin or macrolides, were in labor, had suspected placental abruptions, had overt chorioamnionitis, or had nonreassuring fetal status on presentation indicating the need for prompt delivery. Patients that received limited azithromycin administration (<2 days) and patients that received extended azithromycin administration (7 days) were compared. All patients otherwise received the institutional standard of 2 days of intravenous ampicillin followed by 5 days of oral amoxicillin. The primary outcome was length of gestational latency, defined as the time from membrane rupture to delivery. The selective secondary outcomes that were evaluated were rates of chorioamnionitis and adverse neonatal outcomes, including sepsis, respiratory distress, necrotizing enterocolitis, intraventricular hemorrhage, and neonatal death. During the study period, 416 cases of preterm premature rupture of membranes were identified. Of the 287 patients who met the inclusion criteria, 165 (57.5%) received limited azithromycin administration, and 122 (42.5%) received extended azithromycin administration. Adjusted median gestational latency was significantly longer for patients who received extended azithromycin administration, extended by >3 days (2.6 days [interquartile range, 2.2-3.1] for limited azithromycin administration vs 5.8 days [interquartile range, 4.8-6.9] for extended azithromycin administration; Among patients with preterm premature rupture of membranes, extended azithromycin administration was associated with increased latency, without any effect on other maternal or neonatal outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Preterm premature rupture of membranes accounts for approximately one-quarter of all preterm deliveries and occurs in 2% to 3% of all pregnancies. With subclinical infection being a suspected cause of preterm premature rupture of membranes, the administration of prophylactic antibiotics is an accepted standard of care to extend the latency period. Historically, erythromycin was used in the antibiotic regimen recommended for women with preterm premature rupture of membranes during expectant management; however, azithromycin has recently been shown to be a suitable alternative.
OBJECTIVE OBJECTIVE
This study aimed to evaluate whether extended azithromycin administration affects the latency time in preterm premature rupture of membranes.
STUDY DESIGN METHODS
This was a retrospective multi-institutional cohort study in Washington, District of Columbia, of patients admitted from January 2012 to December 2019 with preterm premature rupture of membranes of singleton pregnancies between 23 0/7 and 33 6/7 weeks of gestation. Patients were excluded if they had multiple pregnancies, had an allergy to penicillin or macrolides, were in labor, had suspected placental abruptions, had overt chorioamnionitis, or had nonreassuring fetal status on presentation indicating the need for prompt delivery. Patients that received limited azithromycin administration (<2 days) and patients that received extended azithromycin administration (7 days) were compared. All patients otherwise received the institutional standard of 2 days of intravenous ampicillin followed by 5 days of oral amoxicillin. The primary outcome was length of gestational latency, defined as the time from membrane rupture to delivery. The selective secondary outcomes that were evaluated were rates of chorioamnionitis and adverse neonatal outcomes, including sepsis, respiratory distress, necrotizing enterocolitis, intraventricular hemorrhage, and neonatal death.
RESULTS RESULTS
During the study period, 416 cases of preterm premature rupture of membranes were identified. Of the 287 patients who met the inclusion criteria, 165 (57.5%) received limited azithromycin administration, and 122 (42.5%) received extended azithromycin administration. Adjusted median gestational latency was significantly longer for patients who received extended azithromycin administration, extended by >3 days (2.6 days [interquartile range, 2.2-3.1] for limited azithromycin administration vs 5.8 days [interquartile range, 4.8-6.9] for extended azithromycin administration;
CONCLUSION CONCLUSIONS
Among patients with preterm premature rupture of membranes, extended azithromycin administration was associated with increased latency, without any effect on other maternal or neonatal outcomes.

Identifiants

pubmed: 37213792
doi: 10.1016/j.xagr.2023.100206
pii: S2666-5778(23)00047-3
pmc: PMC10193115
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100206

Informations de copyright

© 2023 The Authors.

Références

Clin Obstet Gynecol. 2011 Jun;54(2):307-12
pubmed: 21508700
Lancet. 2001 Mar 31;357(9261):979-88
pubmed: 11293640
Lancet. 1995 Nov 11;346(8985):1271-9
pubmed: 7475723
Am J Obstet Gynecol. 2010 Oct;203(4):361.e1-361.e30
pubmed: 20673868
AJP Rep. 2019 Jan;9(1):e67-e71
pubmed: 30854246
Infect Dis Obstet Gynecol. 2020 Jul 9;2020:2093530
pubmed: 32694907
Placenta. 2006 Nov-Dec;27(11-12):1037-51
pubmed: 16516962
J Matern Fetal Neonatal Med. 2017 Sep;30(18):2212-2218
pubmed: 27687157
Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):349-52
pubmed: 9988799
Lancet. 2008 Jan 5;371(9606):75-84
pubmed: 18177778
Cochrane Database Syst Rev. 2003;(2):CD001058
pubmed: 12804398
Lancet. 1980 Jan 26;1(8161):192-4
pubmed: 6101643
Obstet Gynecol. 2014 Sep;124(3):515-519
pubmed: 25162251
Am J Obstet Gynecol. 2019 Aug;221(2):144.e1-144.e8
pubmed: 30904320
J Matern Fetal Neonatal Med. 2016 Mar;29(5):707-20
pubmed: 26373262
JAMA. 1997 Sep 24;278(12):989-95
pubmed: 9307346
J Matern Fetal Neonatal Med. 2006 Aug;19(8):453-64
pubmed: 16966109
Am J Reprod Immunol. 2010 Jul 1;64(1):38-57
pubmed: 20331587
Semin Perinatol. 1996 Oct;20(5):426-38
pubmed: 8912997
Am J Perinatol. 2017 Sep;34(11):1102-1107
pubmed: 28637060
Semin Perinatol. 1996 Oct;20(5):344-68
pubmed: 8912989
Obstet Gynecol. 2020 Mar;135(3):e80-e97
pubmed: 32080050

Auteurs

Alison J DiSciullo (AJ)

Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, DC (Drs DiSciullo, Iqbal, and Chornock).

Marissa Hand (M)

Georgetown University School of Medicine, Washington, DC (Dr Hand).

Sara N Iqbal (SN)

Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, DC (Drs DiSciullo, Iqbal, and Chornock).

Rebecca L Chornock (RL)

Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, DC (Drs DiSciullo, Iqbal, and Chornock).

Classifications MeSH